These genetic targeting methods allowed us to investigate the role of the CD11b+Gr-1− myeloid cells in brain tumor progression and recurrence after pro-drug GCV chemotherapy in our established astrocytoma model. This evidence concerns the gene ITGAM and astrocytoma (excluding glioblastoma).